Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: Dr Schiffmann and colleagues1 reported that intravenous administration of α-galactosidase
A has a number of beneficial effects in patients with Fabry disease. However,
it would be of interest to know the extent of the patients' cutaneous lesions2,3 and whether they were affected
by treatment with α-galactosidase A.
Möhrenschlager M, Ring J, Abeck D. Skin Manifestations of Fabry Disease. JAMA. 2001;286(11):1315. doi:10.1001/jama.286.11.1311